Dantrolene (Na)

Drug #212

Dantrolene (Na) is a hydantoin derivative. Dantrolene (Na) is a neuromuscular blocking agent. It relaxes muscles and relieves pain and discomfort associated with muscle spasms because of some nerve disorders such as multiple sclerosis or spinal cord injuries or may be given for special cases of high fever.

← Previous drug Next drug →

Primary Characteristics

Dantrolene (Na) is also known as Dantrolene sodium.

It is of Synthetic origin and belongs to Imidazolidinedione.

It is classified in Muscle Relaxants pharmacological group.

Molecular Weight: 337 · pK_a: 7.5 · Non-proprietary name: Dantrolene (Na).

Pharmacokinetics

Absorption: Dantrolene (Na) has an oral bioavailability is 35% (±35%).

Distribution: Dantrolene (Na) has a volume of distribution is ~1.2 l/kg. plasma protein binding is 80-90%.

Elimination: it is metabolised via extensive,hepatic, plasma half-life is 8.7 hr, renal excretion is 20%.

Indications

Dantrolene (Na) is primarily indicated in conditions like Chronic and severe spasticity, Malignant hyperthermia, Neuroleptic malignant syndrome, Prostate cancer, long-term palliative therapy, Tetanus.

Contraindications

Dantrolene (Na) is contraindicated in conditions like Spasticity of functional use, Hepatic dysfunction, Muscle spasm in rheumatic conditions.

Dosage

Dantrolene (Na)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
3.036 mg/kg	3.036 mg/kg	—	PO	Per Week for 7 Weeks.
Paediatric Dosage (20kg)
500 mg/kg	500 mg/kg	Every 1h		Increased gradually if necessary to 2mg/kg 3 or 4 times daily but a dose of 100 mg 4 times a daily
Neonatal Dosage (3kg)
No data.

Drug Interactions

Unknown2 interactions

1 interaction

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Dantrolene (Na) in overdosage may give rise to further complications which include Diarrhoea , Tachycardia , Pleural effusion , Seizures , Depression , Urinary retention, Pericardial effusions , Intestinal obstruction , Hematuria, Exacerbation of seizures , Unsatable BP, Urinary retention.

Dantrolene (Na) produces potentially life-threatening effects which include Hepatotoxicity , Pleural effusion with pericarditis. Careful monitoring is needed with proper medical management.

The signs and symptoms that are produced after acute overdosage of Dantrolene (Na) are Unconsciousness, Paralysis of skeletal muscles.

Dantrolene (Na) is known to cause more or less tolerable side effects which are usually transient. These include Abdominal cramps, Anorexia , Chills, Confusion, Constipation , Dizziness, Drowsiness, Fatigue, Insomnia, Malaise, Muscle weakness, Nausea, Nervousness, Pruritus , Vision disturbances, Vomiting , Weakness.

Warnings / Precautions

Dantrolene should be used with caution in patients with impaired pulmonary function, cardiac disease or liver disease. Patient should observe caution while driving or performing other tasks requiring alertness. Photosensitization occurs, so caution patient to take protective measures (sunscreen etc.) against exposure to UV or sunlight.

Interference in Pathology

Dantrolene (Na) may interfere in the diagnosis of changes in ECG & serum electrolytes.

Available Brands

None recorded.

Storage Conditions

Dantrolene (Na) should be stored Caps.

Drug Classification

1.20 — Muscle relaxants and cholinesterase inhibitors